Pharma Research Library | Pharma Info Index Research | Innovation | Opportunities |
J. Praveen Kumar*, M. Charitha1, M. Yashoda Rani2, N. Sujani3, G. Maheswari3
*Associate Professor, Krishna Teja Pharmacy College, Tirupati, A.P., India.
1Srinivasa Institute of Pharmaceutical Sciences, Proddatur, A.P., India.
2Assistant Professor, Mother Theresa Institute of Pharmaceutical Education & Research, Kurnool, A.P., India.
3Assistant Professor, Srinivasa Institute of Pharmaceutical Sciences, Proddatur, A.P., India.
A B S T R A C T
The demand of fast dissolving tablets has been growing, during the last decade especially for geriatric and pediatric patients because of swallowing difficulties. Naproxen is a Propanoic acid derivative related to the arylacetic acid group of Non-Steroidal Anti-Inflammatory Drugs. It is a selective Cox-2 inhibitor used in the treatment of rheumatoid arthritis and other rheumatic or musculo skeletal disorders, dysmenorrheal and acute gout. Fast dissolving tablets of Naproxen were prepared by Wet granulation method. The tablets were prepared by using Mannitol as filler, Crospovidone, Sodium Starch Glycolate as super disintegrants in different concentration (6-8-10 %). Total eighteen formulations were prepared and evaluated for Hardness, friability, weight variation, content uniformity, wetting time, water absorption ratio and disintegration time and in-vitro drug release. Optimized formulation CP10H1 was compared with control formulation for disintegration time and % drug release. The stability studies were performed as per ICH guidelines. The Optimized formulation (CP10H1) showed no significant variations for the tablets parameters and it was stable for the specified time period. It was concluded the FDT for Naproxen can be formulated for emergency treatment of rheumatoid arthritis and acute gout.
Keywords: Gout, Naproxen, Patient, Formulation, ICH guidelines
